COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that epcoritamab, a T-cell engaging bispecific antibody, has been added to the National Comprehensive Cancer Network ® ...

The NCCN Guidelines for MPNs have seen frequent updates recently, reflecting new therapeutic approvals and options for patients. Emphasis on clinical trials as preferred treatment options highlights ...

A strong recommendation was made for fixed-dose topical combination therapies as these agents could help with adherence, and in some cases, may be less expensive than prescribing the individual ...